Acute tumor lysis syndrome after rituximab administration in Burkitt's lymphoma.
Otrock
Zaher K
ZK
Hatoum
Hassan A
HA
Salem
Ziad M
ZM
D000208:Acute Disease; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002051:Burkitt Lymphoma / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D000069283:Rituximab; D015275:Tumor Lysis Syndrome / Q000188:drug therapy / Q000209:etiology*
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab